Cardiovascular Benefits of GLP-1 Agonists Beyond Glycemic Control
Large trials show these drugs protect hearts and kidneys beyond glucose.
Saoirse Dunleavy
Section
9 stories in GLP-1 Biology.
Large trials show these drugs protect hearts and kidneys beyond glucose.
Trials show real promise in Parkinson's but falter in Alzheimer's.
Two receptors beat one on weight loss, but not on heart data.
How engineers outlasted DPP-4 and the kidney to make GLP-1 a drug.
Three enzymes dismantle GLP-1, and fixing one isn't enough.
Most patients quit GLP-1 drugs within a year, long before they can work.
Three distinct pathways drive GLP-1 nausea, and each needs its own fix.
A look at who leads the GLP-1 market and why patients quit.
Mapping where the receptor sits explains what GLP-1 drugs can do.